In a phase I clinical trial enrolling 28 patients with stable metastatic breast cancer (mBC), the efficacy of a combination therapy using an allogenic GM-CSF-secreting BC vaccine along with chemotherapy was investigated (63). The gene discussed is CSF2; the disease is breast cancer.